当前位置: X-MOL 学术Expert Rev. Mol. Diagn. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Bladder neoplasms and NF-κB: an unfathomed association.
Expert Review of Molecular Diagnostics ( IF 5.1 ) Pub Date : 2020-04-12 , DOI: 10.1080/14737159.2020.1743688
Charles Emmanuel Jebaraj Walter 1 , Sankari Durairajan 1 , Kalaiselvi Periyandavan 2 , George Priya Doss C 3 , Dicky John Davis G 1 , Hannah Rachel Vasanthi A 4 , Thanka Johnson 1 , Hatem Zayed 5
Affiliation  

Introduction: Bladder cancer is the second most common genitourinary tract cancer and is often recurrent and/or chemoresistant after tumor resection. Cigarette smoking, exposure to aromatic amines, and chronic infection/inflammation are bladder cancer risk factors. NF-κB is a transcription factor that plays a critical role in normal physiology and bladder cancer. Bladder cancer patients have constitutively active NF-κB triggered by pro-inflammatory cytokines, chemokines, and hypoxia, augmenting carcinogenesis and progression.Areas covered: NF-κB orchestrates protein interactions (PTEN, survivin, VEGF), regulation (CYLD, USP13) and gene expression (Trp 53) resulting in bladder cancer progression, recurrence and resistance to therapy. This review focuses on NF-κB in bladder inflammation, cancer and resistance to therapy.Expert opinion: NF-κB and bladder cancer necessitate further research to develop better diagnostic and treatment regimens that address progression, recurrence and resistance to therapy. NF-κB is a master regulator that can act with or on minimally one cancer hallmark gene or protein, leading to bladder cancer progression (Tp53, PTEN, VEGF, HMGB1, CYLD, USP13), recurrence (PCNA, BcL-2, JUN) and resistance to therapy (P-gp, twist, SETD6). Thus, an understanding of bladder cancer in relation to NF-κB will offer improved strategies and efficacious targeted therapies resulting in minimal progression, recurrence and resistance to therapy.

中文翻译:

膀胱肿瘤和 NF-κB:一种深不可测的关联。

简介:膀胱癌是第二常见的泌尿生殖道癌症,在肿瘤切除后通常会复发和/或耐药。吸烟、接触芳香胺和慢性感染/炎症是膀胱癌的危险因素。NF-κB 是一种转录因子,在正常生理和膀胱癌中起关键作用。膀胱癌患者具有由促炎细胞因子、趋化因子和缺氧触发的组成型活性 NF-κB,从而增强癌发生和进展。涵盖的领域:NF-κB 协调蛋白质相互作用(PTEN、存活蛋白、VEGF)、调节(CYLD、USP13)和基因表达 (Trp 53) 导致膀胱癌进展、复发和对治疗的抵抗。本综述重点关注 NF-κB 在膀胱炎症、癌症和耐药性中的作用。 专家意见:NF-κB 和膀胱癌需要进一步研究以开发更好的诊断和治疗方案,以解决进展、复发和治疗耐药性问题。NF-κB 是一种主要调节因子,可以与或至少作用于一个癌症标志基因或蛋白质,导致膀胱癌进展(Tp53、PTEN、VEGF、HMGB1、CYLD、USP13)、复发(PCNA、BcL-2、JUN)和对治疗的抵抗(P-gp、twist、SETD6)。因此,了解与 NF-κB 相关的膀胱癌将提供改进的策略和有效的靶向治疗,从而最大限度地减少进展、复发和治疗耐药性。NF-κB 是一种主要调节因子,可以与或至少作用于一个癌症标志基因或蛋白质,导致膀胱癌进展(Tp53、PTEN、VEGF、HMGB1、CYLD、USP13)、复发(PCNA、BcL-2、JUN)和对治疗的抵抗(P-gp、twist、SETD6)。因此,了解与 NF-κB 相关的膀胱癌将提供改进的策略和有效的靶向治疗,从而最大限度地减少进展、复发和治疗耐药性。NF-κB 是一种主要调节因子,可以与或至少作用于一个癌症标志基因或蛋白质,导致膀胱癌进展(Tp53、PTEN、VEGF、HMGB1、CYLD、USP13)、复发(PCNA、BcL-2、JUN)和对治疗的抵抗(P-gp、twist、SETD6)。因此,了解与 NF-κB 相关的膀胱癌将提供改进的策略和有效的靶向治疗,从而最大限度地减少进展、复发和治疗耐药性。
更新日期:2020-04-12
down
wechat
bug